

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Loren J. Field et al.

Application No. 10/080,943

Filed February 22, 2002

p193 PROTEINS AND NUCLEIC
ACIDS, AND USES THEREOF

)
) Before the Examiner:
) Joseph T. Voitach
)
) Group Art Unit
) 1632
)
)
) Attorney Docket. No. 7037-458
)


INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:


Pursuant to the duty of disclosure in accordance with 37 CFR §1.56, Applicant wishes to bring to the attention of the Examiner the publications listed on the attached Form PTO/SB/08b. Copies of cited items are enclosed in accordance with 37 CFR §1.98.

The filing of this Information Disclosure Statement shall not be construed as an admission that the information cited is, or is considered to be, material to patentability as defined in §1.56(b).

"Express Mail" label number	EV 466870343 US
Date of Deposit	December 2, 2005
<p>I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated above and is addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.</p>	
	
Signature of person mailing paper or fee	

This Information Disclosure Statement is being submitted after the mailing date of a Final Office Action. Thus, a Request for Continued Examination (RCE) and the fee of 37 CFR §1.17(e) are being filed herewith. It is believed that no fee is required for consideration of the submitted items. If any fees are deemed necessary, the U. S. Patent & Trademark Office is hereby authorized to charge such fees to Deposit Account No. 23-3030, but not to include any payment of issue fees that are or may become due.

Respectfully submitted,

By: 
John J. Emanuele
Woodard, Emhardt, Moriarty, McNett & Henry LLP
3700 Bank One Center Tower
111 Monument Circle
Indianapolis, IN 46204-5137
(317) 634-3456



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/080,943
				Filing Date	February 22, 2002
				First Named Inventor	Loren J. Field et al.
				Art Unit	1632
				Examiner Name	Joseph T. Voitach
Sheet	1	of	1	Attorney Docket No.	7037-458

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published	T ⁶
		TSAI, Shih-Chong, "Tumor Suppressor Pathway in Myocardium (RAD50, Phosphoproteins)", <i>Dissertation Abstracts International</i> , February 1999, AAD99-19502, pgs. 190-193, Figures 1D and 1E, Michigan.	<input type="checkbox"/>
		NOMURA, N. et al., "Human mRNA for KIAA0076 Gene, Complete CDS." <i>Database EMBL 'Online!'</i> , Retrieved from EBI, November 3, 1994, EBI Database Accession No. D38548, abstract	<input type="checkbox"/>
		TSAI, Shih-Chong et al., "Simian virus 40 large T antigen binds a novel Bc1-2 homology domain 3-containing proapoptosis protein in the cytoplasm.", <i>Journal of Biological Chemistry</i> , Vol. 275, No. 5, February 4, 2000, pgs. 3239-3246.	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional).

²Applicant is to place a check mark here if English language Translation is attached.